Monoclonal antibody-based therapy for renal cell carcinoma

Urologic Clinics of North America

Volumn 30, Issue 3, 2003, Pages 623-631

  Oosterwijk, Egbert ^a   Divgi, Chaitanya R ^b   Brouwers, Adrienne ^c   Boerman, Otto C ^c   Larson, Steven M ^b   Mulders, Peter ^c   Old, Lloyd J ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; CANCER THERAPY; CELL KILLING; CELL PROLIFERATION; COHORT ANALYSIS; DRUG ACCUMULATION; DRUG CROSS REACTIVITY; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TARGET CELL;

EID: 0042821653     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00028-4     Document Type: Review

References (49)

1. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86.
2. Nishiyama K, Shirahama T, Yoshimura A, Sumizawa T, Furukawa T, Ichikawa-Haraguchi M, et al. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 1993;71:3611-9.
3. Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999;10:1159-69.
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
5. Ehrlich P. On immunity with special reference to cell life. In: Himmelweit F, Marquardt M, Dale H, editors. The collected papers of Paul Ehrlich, vol. II. Immunology and cancer research. London: Pergamon Press; 1957.
6. Boon T, Coulie PG, Van den EB. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-8.
7. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000;85:460-5.
8. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000;83:493-7.
9. Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000;150:155-64.
10. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989;37:77-104.
11. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-9s.
12. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
13. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 1990;8:1894-906.
14. Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-lb for the treatment of metastatic renal cell carcinoma: the Canadian Urologic Oncology Group. BJU Int 2000;86:613-8.
15. Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Li LT, Whitmore WF, et al. Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 1979;150:564-79.
16. Bernhard H, Maeurer MJ, Jager E, Wolfel T, Schneider J, Karbach J, et al. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scand J Immunol 1996;44:285-92.
17. Brouwenstijn N, Hoogstraten C, Verdegaal EM, Van der Spek CW, Deckers JG, Mulder A, et al. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma. J Immunother 1998;21:427-34.
18. Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, et al. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 1990;50:2363-70.
19. Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11.
20. Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996;44:323-30.
21. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
22. Bander NH, Cordon-Cardo C, Finstad CL, Whitmore WF Jr., Vaughan ED Jr., Oettgen HF, et al. Immunohistologic dissection of the human kidney using monoclonal antibodies. J Urol 1985;133:502-5.
23. Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr., Whitmore WF Jr., et al. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. Cancer Res 1989;49:6774-80.
24. Finstad CL, Cordon-Cardo C, Bander NH, Whitmore WF, Melamed MR, Old LJ. Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci USA 1985;82:2955-9.
25. Fischer P, Storkel S, Haase W, Scherberich JE. Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against gamma-glutamyltransferase. Cancer Immunol Immunother 1991;33:382-8.
26. Kinouchi T, Nakayama E, Ueda R, Ishiguro S, Uenaka A, Oda H, et al. Characterization of a kidney antigen defined by a mouse monoclonal antibody K2.7. J Urol 1987;137:151-4.
27. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, et al. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489-94.
28. Oosterwijk E, Ruiter DJ, Wakka JC, Huiskensvan der Meij JW, Jonas U, Fleuren GJ, et al. Immunohistochemical analysis of monoclonal antibodies to renal antigens: application in the diagnosis of renal cell carcinoma. Am J Pathol 1986;123:301-9.
29. Tokuyama H, Tokuyama Y. Mouse monoclonal antibodies with restricted specificity for human renal cell carcinoma and ability to modulate the tumor cell growth in vitro. Hybridoma 1988;7:155-65.
30. Vessella RL, Lange PH, Palme DF, Chiou RK, Elson MK, Wessels BW. Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice. Targeted Diagn Ther 1988;1:245-82.
31. Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res 1989;49:1802-9.
32. Chiou RK. Biodistribution and radioimmunoscintigraphy studies of renal cell carcinoma using tumor-preferential monoclonal antibodies and F(ab')2 fragments. J Urol 1989;142:1584-8.
33. Rachel U, Baum RP, Fischer P, Jonas D, Scherberich JE. Monoclonal antibody 138H11 in immunoscintigraphy of human kidney tumors - in vitro results. Investig Urol (Berl) 1994;5:66-8.
34. Vessella RL, Moon TD, Chiou RK, Nowak JA, Arfman EW, Palme DF, et al. Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens. Cancer Res 1985;45:6131-9.
35. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741-6.
36. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000;85:865-70.
37. Kranenborg MH, Boerman OC, De Weijert MC, Oosterwijk-Wakka JC, Corstens FH, Oosterwijk E. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997;80:2390-7.
38. Steffens MG, Kranenborg MH, Boerman OC, Zegwaart-Hagemeier NE, Debruyne FM, Corstens FH, et al. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 1998;13:133-9.
39. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, Debruyne FM, Corstens FH, et al. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 1999;19:1197-200.
40. van Dijk J, Oosterwijk E, van Kroonenburgh MJ, Jonas U, Fleuren GJ, Pauwels EK, et al. Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J Nucl Med 1988;29:1078-82.
41. van Dijk J, Uemura H, Beniers AJ, Peelen WP, Zegveld ST, Fleuren GJ, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994;56:262-8.
42. van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991;48:738-43.
43. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993;11:738-50.
44. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729-39.
45. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529-37.
46. Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 1311-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5:3268s-74s.
47. Steffens MG, Boerman OC, Oyen WJ, Kniest PH, Witjes JA, Oosterhof GO, et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999;59:1615-9.
48. Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002;51:171-7.
49. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates anti-body-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996;19:184-91.